Kymera Therapeutics (KYMR) has a market capitalization of approximately $9.1B, trading at
Kymera Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Kymera Therapeutics runs a net profit margin of -612.2%, a gross margin of 100.0%, and an operating margin of -697.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Kymera Therapeutics reported revenue of
Kymera Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Kymera Therapeutics carries a debt-to-equity ratio of 0.05x and a current ratio of 10.81x, with a market beta of 1.96. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kymera Therapeutics (KYMR) the key facts are: market cap $9.1B, revenue
Get Kymera Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.